GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

penpulimab   Click here for help

GtoPdb Ligand ID: 12347

Synonyms: AK-105 | AK105 | Aniko® [1] | penpulimab-kcqx
Approved drug Immunopharmacology Ligand
penpulimab is an approved drug
Compound class: Antibody
Comment: Penpulimab (AK-105) is a chimeric IgG1κ programmed cell death 1 (PD-1) monoclonal antibody [2]. Its engineered Fc structure means that it does not interact with Fcγ receptors and therefore it does not induce immune cell (macrophage) effector functions (antibody-dependent cell-mediated cytotoxicity/ADCC, antibody-dependent cellular phagocytosis/ADCP, antibody-dependent cytokine release/ADCR). Penpulimab binds to an epitope in human PD-1's N-glycosylation site (at residue N58).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Penpulimab was granted its first clinical approval in China (August 2021) [1]. It was indicated to treat nasopharyngeal cancer and NSCLC at that time. FDA approval followed in April 2025, with penpulimab-kcqx indicated for recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04974398 A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Phase 3 Interventional Akeso